TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25517820
Drug: RMP formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP formulation E
Study: 25517820
Drug: INH formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH formulations A, B, C, and D
Study: 25517820
Drug: RMP formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP formulations A, B, C, and D
Study: 25517820
Drug: INH formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH formulation E
Study: 20230611
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review and cognitive behaviour therapy by community pharmacists
Study: 20230611
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Treatment
Study: 20230611
Drug: Medication Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Adherence Report Scale Questionnaire
Study: 9376578
Drug: Intensive Consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Consolidation Chemotherapy (ICC)
Study: 3935869
Drug: Buserelin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (2 X 1 mg subcutaneously after parenteral treatment with 3 mg per day in the first week)
Study: 3935869
Drug: Buserelin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (3 X 400 micrograms intranasally) + Tamoxifen (2 X 20 mg)
Study: 3935869
Drug: Buserelin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (3 X 400 micrograms intranasally) + Megestrol acetate (4 X 45 mg)
Study: 27080498
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² on day 1 and day 6 during the first two courses of chemotherapy) plus chemotherapy (lymphome malin B [LMB])
Study: 27080498
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (no rituximab)
Study: 17611322
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with midazolam (Group A and B: 16-25 mg/10s; Group C and D: 6-7 mg/10s)
Study: 10597550
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1 followed by a maintenance infusion of 5 mg.kg‐1.h‐1
Study: 8567345
Drug: Preoperative concomitant
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concomitant radiochemotherapy (two courses of 18.5 Gy in five fractions, continuous infusion of 5-FU 800 mg/m2 days 1-5 and cisplatinum 70 mg/m2 day 2)
Study: 1824249
Drug: Cytarabine (Ara‐C)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine (Ara‐C) 100 mg/m2 (A100)
Study: 1824249
Drug: Cytarabine (Ara‐C)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine (Ara‐C) 200 mg/m2 (A200)
Study: 29525617
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide administered 1 hour preoperatively
Study: 29525617
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide administered 3 hours postoperatively
Study: 29525617
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration of acetazolamide
Study: 26340097
Drug: Oral solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solifenacin succinate 5 mg/day
Study: 24196466
Drug: Topical (intra-articular)
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical (intra-articular) tranexamic acid
Study: 16481638
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant interferon alfa-2b
Study: 15215813
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg and 10 mg
Study: 15215813
Drug: Rosuvastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (all doses)
Study: 10974371
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral treatment
Study: 30534008
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg
Study: 22595363
Drug: Galantamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8 mg/day for 4 weeks, then 16 mg/day for 12 weeks)
Study: 20704493
Drug: dTpa vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa vaccine
Study: 25424783
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A control vaccine
Study: 12413615
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of mifepristone alone (Group 1)
Study: 12413615
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tamoxifen with 10 mg of mifepristone (Group 2)
Study: 9042043
Drug: Budesonide via
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide via Turbuhaler (0.4, 0.8, 1.6, and 2.4 mg/day for 2 weeks)
Study: 7930659
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of aspirin per day
Study: 31350828
Drug: Early intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensive antihypertensive treatment (100 mg urapidil and 30 mL of 0.9% sodium chloride after initial 25 mg urapidil injection)
Study: 31350828
Drug: Early intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensive antihypertensive treatment
Study: 31350828
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (25 mg urapidil injection)
Study: 29322620
Drug: Spent hops-rice
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spent hops-rice protein matrix preparation
Study: 29322620
Drug: Control spent
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control spent hops preparation
Study: 26597151
Drug: Low-dose lipopolysaccharide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lipopolysaccharide (LPS) 0.4 ng/kg
Study: 30682067
Drug: Treatment‐as‐usual (TAU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment‐as‐usual (TAU)
Study: 21156883
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation
Study: 21156883
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of oral antihyperglycemic agents
Study: 17389205
Drug: Topical papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical papaverine application at room temperature
Study: 17389205
Drug: Topical heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heated papaverine (at 37 degrees C) application
Study: 17389205
Drug: Pedicle storage
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicle storage in normothermic conditions combined with topical papaverine application
Study: 17389205
Drug: Pedicle storage
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicle storage in normothermic conditions combined with topical heated papaverine application
Study: 17389205
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, stored at room temperature)
Study: 15647189
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (Bifidobacterium longum/Synergy 1)
Study: 12374247
Drug: Oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonates
Study: 24311451
Drug: Big breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Big breakfast (BB) rich in fat and protein providing 33% of total daily energy
Study: 24311451
Drug: Small breakfast
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small breakfast (SB) rich in carbohydrates providing 12.5% of total daily energy
Study: 22445437
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing levonorgestrel and EE
Study: 14969377
Drug: Listerine Oral
Normalized name: Listerine Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine Oral Care Strip
Study: 14969377
Drug: Saturated Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated Saline Solution
Study: 11159485
Drug: Standard method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard method of performing the TFI with and without topical anaesthetic
Study: 2905879
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg twice daily
Study: 2905879
Drug: Bopindolol 1
Normalized name: bopindolol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 1 mg daily
Study: 26315876
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (50 mg/kg)
Study: 26315876
Drug: Control (rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rocuronium 0.6 mg/kg)
Study: 26315876
Drug: Rocuronium prime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium prime (0.06 mg/kg rocuronium 3 minutes before 0.54 mg/kg rocuronium)
Study: 26315876
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 (0.9 mg/kg)
Study: 21241263
Drug: No oxytocic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxytocic agent (control group)
Study: 18278988
Drug: Acute bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute bilateral electroconvulsive therapy (ECT)
Study: 17103080
Drug: Hempseed oil
Normalized name: OPHIOCORDYCEPS SINENSIS 0.1 g ORAL CAPSULE [HempSeed Cordyceps]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hempseed oil (HO) 30 ml/day for 4 weeks
Study: 17103080
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FO) 30 ml/day for 4 weeks
Study: 12924534
Drug: Nebulized zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nebulized zanamivir (16 mg four times a day) plus rimantadine
Study: 11070372
Drug: sipatrigine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sipatrigine (10, 18, 27, or 36 mg/kg by continuous intravenous infusion over 65 hours)
Study: 8622153
Drug: AVS (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVS (4 g, infused intravenously for 6-8 hours once a day for 10 to 14 days)
Study: 8622153
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g glucose, infused intravenously for 6-8 hours once a day for 10 to 14 days)
Study: 1567268
Drug: Gentian violet
Normalized name: Gentian Violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentian violet mouth washes (1.5 ml 0.5% aqueous solution b.i.d.)
Study: 1567268
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole (200 mg/day, after a meal)
Study: 1567268
Drug: Nystatin mouth
Normalized name: DIPHEN/LIDOCAINE/NYSTATIN MOUTHWASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin mouth washes (200,000 U oral suspension q.i.d.)
Study: 24438754
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement of 40 mg/d
Study: 24438754
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement of 80 mg/d
Study: 24438754
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement of 20 mg/d
Study: 24438754
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement of 40 mg/d (Stratum #1)
Study: 24438754
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement of 40 mg/d (Stratum #2)
Study: 22710812
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of 18 compound amino acids (group AA)
Study: 22710812
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (group LR)
Study: 19436119
Drug: IVIG 2
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 2 g/kg for 1 day
Study: 19436119
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg for 1 day
Study: 19436119
Drug: IVIG 400
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 400 mg/kg/day for 5 days
Study: 19436119
Drug: No IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IVIG administration
Study: 11923801
Drug: Azimilide 125
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 125 mg
Study: 8771231
Drug: Cortisol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (3 mg/h)
Study: 2170104
Drug: Instant bean
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant bean flakes (40 g starch)
Study: 2170104
Drug: Potato flakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato flakes (40 g starch)
Study: 6389484
Drug: Controlled-release theophylline
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release theophylline preparation U (Uniphyl tablets) once daily, 800 mg
Study: 6389484
Drug: Controlled-release theophylline
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release theophylline T-D (Theo-Dur tablets) administered 12-hourly, 800 mg
Study: 30303904
Drug: IV sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sedation (100 micrograms fentanyl and 2 mg midazolam)
Study: 26783318
Drug: Intravenous rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rt-PA (alteplase)
Study: 25303029
Drug: Capsules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing VFB
Study: 22760386
Drug: 3M DuraPrep
Normalized name: Iodine Povacrylex 6.02 mg in 1 mL / Isopropyl Alcohol 636.4 mg in 1 mL TOPICAL SOLUTION [3M DuraPrep Surgical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M DuraPrep Surgical Solution Patient Preoperative Skin Preparation
Study: 22760386
Drug: ChloraPrep with
Normalized name: ChloraPrep
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChloraPrep with Tint (Scrub Teal) Patient Preoperative Skin Preparation
Study: 17914062
Drug: MK-0974 300
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0974 300 mg
Study: 17914062
Drug: MK-0974 400
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0974 400 mg
Study: 17914062
Drug: MK-0974 600
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0974 600 mg
Study: 9385350
Drug: Low-dose cladribine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cladribine (2‐CdA) at a dosage of 0.05 mg/kg subcutaneously weekly for 8 weeks
Study: 2975949
Drug: Warfarin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (n = 56)
Study: 29735215
Drug: MMF dispersible
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF dispersible tablets (MMFdt)
Study: 29735215
Drug: MMF capsules
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF capsules (MMFc)
Study: 22278741
Drug: simvastatin alone
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin alone (40 mg/day)
Study: 22278741
Drug: ezetimibe/simvastatin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day)
Study: 25534866
Drug: ezetimibe/simvastatin 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/40 mg/day
Study: 17635889
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 1537) received a telephone counseling program with cooking classes and newsletters promoting dietary targets of 5 vegetable servings, 3 fruit servings, 30 g of fiber, and 15%-20% energy from fat.
Study: 2511698
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg nitroglycerine patch (70% drug release during the first 12 h)
Study: 2511698
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg nitroglycerine patch (subchronic application)
Study: 1103709
Drug: Orphenadrine/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orphenadrine/Paracetamol
Study: 31368382
Drug: ICBTi (Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICBTi (Internet-based cognitive behavioral therapy for insomnia)
Study: 28606961
Drug: Disease activity-guided
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity-guided dose reduction (DR)
Study: 24255998
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and medical management only (Control)
Study: 21879261
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with cisplatin and 5-fluorouracil (group 1)
Study: 21879261
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with cisplatin and 5-fluorouracil (group 2)
Study: 8072048
Drug: Placebo acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acupuncture treatment
Study: 14756912
Drug: Lingzhi supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingzhi supplementation (1.44 g Lingzhi/d; equivalent to 13.2 g fresh mushroom/d)
Study: 7792309
Drug: Raloxifene (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (200 mg daily for 10 days)
Study: 7792309
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg twice a day for 10 days)
Study: 31607205
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily for 18 months
Study: 12497780
Drug: Indapamide 1.5
Normalized name: indapamide 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.5 mg daily
Study: 21994128
Drug: Intraocular fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular fluocinolone acetonide implant
Study: 19292785
Drug: PUVA maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA maintenance treatment (irradiation twice weekly and then once weekly for 4 weeks)
Study: 17716323
Drug: Synera patch
Normalized name: lidocaine / tetracaine Medicated Patch [Synera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synera patch (lidocaine 70 mg and tetracaine 70 mg, 20-minute treatment)
Study: 17716323
Drug: Placebo (20-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20-minute treatment)
Study: 17716323
Drug: Synera patch
Normalized name: lidocaine / tetracaine Medicated Patch [Synera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synera patch
Study: 15244013
Drug: Cetraxate plus
Normalized name: Cetraxal
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetraxate plus clarithromycin and amoxicillin (CCA group)
Study: 15244013
Drug: Pantoprazole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole plus clarithromycin and amoxicillin (PCA group)
Study: 9512152
Drug: Adjunctive subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive subconjunctival mitomycin C
Study: 9512152
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive mitomycin C
Study: 1729932
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg ketamine
Study: 1729932
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg ketamine
Study: 3838120
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of the drug
Study: 29937430
Drug: sotagliflozin 400
Normalized name: sotagliflozin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotagliflozin 400 mg
Study: 25633683
Drug: empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 25 mg
Study: 31854356
Drug: MIS seven
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIS seven implants
Study: 31854356
Drug: Alphadent active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphadent active implants
Study: 26249765
Drug: Rabeprazole sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole sterile powder for injection (RSPI) 10 mg
Study: 26249765
Drug: Rabeprazole sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole sterile powder for injection (RSPI) 20 mg
Study: 26249765
Drug: Rabeprazole sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole sterile powder for injection (RSPI) 40 mg
Study: 26249765
Drug: Rabeprazole sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole sterile powder for injection (RSPI) multiple doses 20 mg
Study: 26249765
Drug: Pariet® 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pariet® 20 mg (control)